Subject And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 2-Way, 4-Period Crossover Study to Assess Effects of PF-02545920 On Ketamine-Induced Aberrant Prefrontal Response To Associative Learning In Healthy Subjects.

Trial Profile

Subject And Investigator-Blinded, Sponsor-Open, Randomized, Single-Dose, Placebo-Controlled, 2-Way, 4-Period Crossover Study to Assess Effects of PF-02545920 On Ketamine-Induced Aberrant Prefrontal Response To Associative Learning In Healthy Subjects.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 May 2014

At a glance

  • Drugs Mardepodect (Primary) ; Ketamine
  • Indications Pain; Schizophrenia
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 20 Mar 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 05 Jun 2012 Planned End Date changed from 1 Nov 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 16 Apr 2012 Planned end date changed from 1 Dec 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top